Evidence map›Paper›PMID 40029709›Full record

ArticleThe Journal of clinical investigation2025

Cathepsin K cleavage of angiopoietin-2 creates detrimental Tie2 antagonist fragments in sepsis.

Takashi Suzuki, Erik Loyde, Sara Chen, Valerie Etzrodt, Temitayo O Idowu, Amanda J Clark, Marie Christelle Saade, Brenda Mendoza Flores, Shulin Lu, Gabriel Birrane and 4 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Molecular Mechanisms of Sepsis-Associated Acute Kidney Injury.Journal of the American Society of Nephrology : JASN · 2025
    Review
  6. Role of Tie-2 Axis in Sepsis: A Potential Therapeutic Target.Journal of cellular and molecular medicine · 2025
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Takashi SuzukiDivision of Nephrology, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
Erik LoydeDivision of Nephrology, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
Sara ChenCenter for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
Valerie EtzrodtDivision of Nephrology, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
Temitayo O IdowuDivision of Nephrology, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
Amanda J ClarkDivision of Nephrology, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
Marie Christelle SaadeDivision of Nephrology, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
Brenda Mendoza FloresDivision of Nephrology, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
Shulin LuCenter for Vascular Biology Research, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
Gabriel BirraneDivision of Experimental Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA.
Vamsidhara VemireddyDivision of Nephrology, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
Benjamin SeeligerDepartment of Respiratory Medicine, Hannover Medical School, Hannover, Germany.
Sascha DavidInstitute of Intensive Care Medicine, University Hospital Zurich, Zurich, Switzerland.
Samir M ParikhDivision of Nephrology, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.

Funding

UT Southwestern NORCP30DK127984 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Jeff G McDonald · 2022 to 2026
$7.4M
The Aging Kidney: Chronic Injury, Impaired Functions and Clinical OutcomesR01AG027002 · NIA · TUFTS MEDICAL CENTER · PI PARIKH, SAMIR M, SARNAK, MARK J · 2005 to 2022
$7.3M
Tie2-driven vascular control in critical illnessR35HL139424 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI PARIKH, SAMIR M · 2018 to 2024
$6.4M
Mitochondrial Biogenesis in Kidney DiseaseR01DK095072 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Samir M Parikh · 2012 to 2026
$5.3M
NHLBI NIH HHS R35 HL139424NIA NIH HHS R01 AG027002NIDDK NIH HHS P30 DK127984NIDDK NIH HHS R01 DK095072
6 · The paper itself

Abstract

Elevated angiopoietin-2 is associated with diverse inflammatory conditions, including sepsis, a leading global cause of mortality. During inflammation, angiopoietin-2 antagonizes the endothelium-enriched receptor Tie2 to destabilize the vasculature. In other contexts, angiopoietin-2 stimulates Tie2. The basis for context-dependent antagonism remains incompletely understood. Here, we show that inflammation-induced proteolytic cleavage of angiopoietin-2 converts this ligand from Tie2 agonist to antagonist. Conditioned media from stimulated macrophages induced endothelial angiopoietin-2 secretion. Unexpectedly, this was associated with reduction of the 75 kDa full-length protein and appearance of new 25 and 50 kDa C-terminal fragments. Peptide sequencing proposed cathepsin K as a candidate protease. Cathepsin K was necessary and sufficient to cleave angiopoietin-2. Recombinant 25 and 50 kDa angiopoietin-2 fragments (cANGPT225 and cANGPT250) bound and antagonized Tie2. Cathepsin K inhibition with the phase 3 small-molecule inhibitor odanacatib improved survival in distinct murine sepsis models. Full-length angiopoietin-2 enhanced survival in endotoxemic mice administered odanacatib and, conversely, increased mortality in the drug's absence. Odanacatib's benefit was reversed by heterologous cANGPT225. Septic humans accumulated circulating angiopoietin-2 fragments, which were associated with adverse outcomes. These results identify cathepsin K as a candidate marker of sepsis and a proteolytic mechanism for the conversion of angiopoietin-2 from Tie2 agonist to antagonist, with therapeutic implications for inflammatory conditions associated with angiopoietin-2 induction.

Indexed as

Angiopoietin-2Cathepsin KReceptor, TIE-2SepsisAnimalsHumansMaleMiceProteolysisAngiopoietin-2ANGPT2 protein, humanCathepsin KReceptor, TIE-2TEK protein, humanTek protein, mouseEndothelial cellsInflammationVascular biology

Identifiers

PMID40029709
PMCPMC11996858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.